Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

1(33%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_3

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(1)

Other(1)

Detailed Status

Completed1

unknown1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 32 (66.7%)

Trials by Status

completed133%

unknown133%

active_not_recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

active_not_recruitingphase_3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986

unknownphase_2

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

NCT05296577

completedphase_3

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

NCT02225470

Clinical Trials (3)

Showing 3 of 3 trials

NCT04639986Phase 3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active Not Recruiting

NCT05296577Phase 2

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

Unknown

NCT02225470Phase 3

Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3